Click to expand view.
ACP is working actively in the field of performance measurement because we recognize its importance in the changing health care environment and want to shape its impact on Internal Medicine. The Performance Measurement Committee oversees the College's activities in this area.
The Performance Measurement Committee (PMC) applies criteria to assess the validity of performance measures for healthcare. The criteria are evaluated with a modified RAND-UCLA appropriateness method to determine whether they are evidence-based, methodologically sound, and clinically meaningful.
Latest Performance Measurement Committee Papers
ACP develops clinical policy papers and performance measurement commentaries published in scientific journals to educate ACP members about performance measurement initiatives.
- Quality Indicators for Pain in Adults (Annals of Internal Medicine, 2024)
- Quality Indicators for Major Depressive Disorder in Adults (Annals of Internal Medicine, 2024)
- Quality Indicators for Osteoporosis in Adults (Annals of Internal Medicine, 2023)
- Performance Measures for Physicians Providing Clinical Care Using Telemedicine (Annals of Internal Medicine, 2023)
- Recommending Caution in Patient-Reported Outcome–Based Performance Measurement (Annals of Internal Medicine, 2021)
- Time Out -- Charting a Path for Improving Performance Measurement (New England Journal of Medicine, 2018)
Help Us Improve Performance Measures
The PMC recognizes the burdens that inadequate measures can create for physicians. We are committed to continually reviewing and improving these measures to better support internal medicine physicians and drive meaningful change.
We value your input. Please take a minute to complete a brief survey
PMC Measure Reviews
This tool has been created to help you filter the reviewed performance measures.
= ACP Supports This Measure
= ACP Does Not Support This Measure: Uncertain Validity
= ACP Does Not Support This Measure
= ACP Does Not Support This Measure: Not Tested
Recent Measure Reviews
- Group/Practice
Depression Response at Twelve Months, Progress Towards Remission
The percentage of adolescent patients (12 to 17 years of age) and adult patients (18 years of age or older) with major depression or dysthymia who are progressing towards remission by achieving a response (PHQ-9 or PHQ-9M score reduced by 50% or greater) twelve months (+/- 60 days) after an index visit.
Date Reviewed: September 28, 2022
- Group/Practice
- Individual Clinician
Depression Utilization of the PHQ-9 Tool
The percentage of adolescent patients (12 to 17 years of age) and adult patients (18 years of age or older) with a diagnosis of major depression or dysthymia who have a completed PHQ-9 tool during a four month measurement period.
Date Reviewed: September 28, 2022
- Group/Practice
- Individual Clinician
Depression Remission at Twelve Months
The percentage of adolescent patients 12 to 17 years of age and adult patients 18 years of age or older with major depression or dysthymia who reached remission 12 months (+/- 60 days) after an index event date.
Date Reviewed: September 28, 2022
- Group/Practice
- Individual Clinician
Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan
Percentage of patients aged 12 years and older screened for depression on the date of the encounter or up to 14 days prior to the date of the encounter using an age-appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the eligible encounter.
Date Reviewed: September 28, 2022
- Group/Practice
- Individual Clinician
Adult Major Depressive Disorder (MDD): Suicide Risk Assessment
All patient visits during which a new diagnosis of MDD or a new diagnosis of recurrent MDD was identified for patients aged 18 years and older with a suicide risk assessment completed during the visit.
Date Reviewed: September 28, 2022
- Health Plan
- Group/Practice
- Individual Clinician
Anti-Depressant Medication Management
"Percentage of patients 18 years of age and older who were treated with antidepressant medication, had a diagnosis of major depression, and who remained on an antidepressant medication treatment. Two rates are reported.
a. Percentage of patients who remained on an antidepressant medication for at least 84 days (12 weeks).
b. Percentage of patients who remained on an antidepressant medication for at least 180 days (6 months).
Date Reviewed: September 28, 2022
- Group/Practice
Depression Remission at Six Months
The percentage of adolescent patients 12 to 17 years of age and adult patients 18 years of age or older with major depression or dysthymia who reached remission six months (+/- 60 days) after an index event date.
Date Reviewed: September 28, 2022
- Group/Practice
Depression Response at Six Months- Progress Towards Remission
The percentage of adolescent patients (12 to 17 years of age) and adult patients (18 years of age or older) with major depression or dysthymia who are progressing towards remission by achieving a response (PHQ-9 or PHQ-9M score reduced by 50% or greater) six months (+/- 60 days) after an index visit.
Date Reviewed: September 28, 2022